| FOSCX | NAESX | FOSCX / NAESX | |
| Total Expense Ratio | 1.18 | 0.17 | 694% |
| Annual Report Gross Expense Ratio | 1.37 | 0.17 | 806% |
| Fund Existence | 30 years | 66 years | - |
| Gain YTD | 25.998 | 14.563 | 179% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 656M | 189B | 0% |
| Annual Yield % from dividends | 0.20 | 1.10 | 18% |
| Returns for 1 year | 18.90 | 22.56 | 84% |
| Returns for 3 years | 16.44 | 43.30 | 38% |
| Returns for 5 years | -2.73 | 34.95 | -8% |
| Returns for 10 years | 40.26 | 155.28 | 26% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| VMMSX | 32.15 | 0.39 | +1.23% |
| Vanguard Emerg Mkts Sel Stk Inv | |||
| VRGWX | 936.97 | 7.54 | +0.81% |
| Vanguard Russell 1000 Growth Index I | |||
| GIDWX | 20.04 | 0.13 | +0.65% |
| Goldman Sachs US Eq Div and Premium R6 | |||
| CAVAX | 18.71 | 0.04 | +0.21% |
| SEI Catholic Values Equity F (SCVT) | |||
| RYOIX | 86.56 | -2.00 | -2.26% |
| Rydex Biotechnology Inv | |||